Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MYC | P01106 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29425530 | 0.87 | HPGD (0.54) | CES2CES1SMN1; SMN2HPGDERCC5 | |
| SCHEMBL166603 | 0.87 | HPGD (0.54) | CES2CES1SMN1; SMN2HPGDERCC5 | |
| Hydrochloric Acid SCHEMBL9391088 | 0.83 | HPGD (0.50) | CES2CES1SMN1; SMN2HPGDERCC5 | |
| SCHEMBL29089128 | 0.83 | HPGD (0.50) | SMN1; SMN2HPGDERCC5FEN1HTT | |
| SCHEMBL4087542 | 0.82 | SMN1; SMN2 (0.46) | SMN1; SMN2HPGDERCC5FEN1HTT | |
| SCHEMBL22416287 | 0.81 | SMN1; SMN2 (0.42) | CES2CES1SMN1; SMN2HPGDERCC5 | |
| SCHEMBL9711362 | 0.81 | ERCC5 (0.57) | SMN1; SMN2HPGDERCC5FEN1HTT | |
| SCHEMBL166031 | 0.81 | ERCC5 (0.57) | SMN1; SMN2HPGDERCC5FEN1HTT | |
| SCHEMBL112406 | 0.80 | HPGD (0.57) | SMN1; SMN2HPGDERCC5FEN1HTT | |
| SCHEMBL29441418 | 0.80 | HPGD (0.57) | SMN1; SMN2HPGDERCC5FEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7695863-B2 | rechargeable batteries having excellent battery cycle properties, electrical capacity and storage characteristic during charging, comprising electrodes and a nonaqueous electrolytic solution containing a dicarbonyl compound as an additive | UBE INDUSTRIES, LTD. (JP) | 2010-04-13 | — | — | US | disclosed |
| US-20100004179-A1 | TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY | GEORGETOWN UNIVERSITY | 2010-01-07 | — | — | US | disclosed |
| CN-100566005-C | The lithium secondary battery of nonaqueous electrolyte solution and this solution of use | UBE INDUSTRIES (JP) | 2009-12-02 | — | — | CN | disclosed |
| US-20080102377-A1 | rechargeable batteries having excellent battery cycle properties, electrical capacity and storage characteristic during charging, comprising electrodes and a nonaqueous electrolytic solution containing a dicarbonyl compound as an additive | UBE INDUSTRIES, LTD (JP) | 2008-05-01 | — | — | US | disclosed |
| CN-101091283-A | Nonaqueous electrolytic solution and lithium secondary battery using the same | UBE INDUSTRIES (JP) | 2007-12-19 | — | — | CN | disclosed |
| EP-1480976-B1 | THIAZOLE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2007-09-19 | — | — | EP | disclosed |
| EP-1480976-B1 | THIAZOLE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2007-09-19 | — | — | EP | disclosed |
| EP-1480976-A1 | THIAZOLE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-12-01 | — | — | EP | disclosed |
| US-6686381-B2 | COMPOUNDS THAT ANTAGONIZE NEUROPEPTIDE Y AT THE Y5 RECEPTOR SUBTYPE REPRESENT AN APPROACH TO THE TREATMENT OF EATING DISORDERS SUCH AS OBESITY AND HYPERPHAGIA | HOFFMANN-LA ROCHE INC. | 2004-02-03 | — | — | US | disclosed |
| US-20030225141-A1 | THIAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003072577-A1 | THIAZOLE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004179-A1 | TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY | EWSR1, FLI1, PELI1 | CES2 4721/4885CES1 3915/4885SMN1; SMN2 1922/4885 |
| US-20030225141-A1 | THIAZOLE DERIVATIVES | SLC5A1, GPR119, TAS1R1 | CES2 1301/4885CES1 137/4885SMN1; SMN2 2375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.